MedTrace Logo

Increasing Dose Tolerance Study in Healthy Male Volunteers After Administration of BIII 890 CL

NCT02268136 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2014-10-20

No results posted yet for this study

Summary

The objective ot the present study is to obtain information about safety, tolerability and preliminary pharmacokinetics of BIII 890 CL after single intravenous administration of increasing doses in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

BIII 890 CL

DRUG

Placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-04-30
Primary Completion
1999-12-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02268136 on ClinicalTrials.gov